Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.26 USD

51.26
3,013,431

-1.59 (-3.01%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $51.26 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Arpita Dutt headshot

Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

by Arpita Dutt

This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

    Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1

    by Zacks Equity Research

    Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.

      Kevin Cook headshot

      Bull of the Day: Regeneron (REGN)

      by Kevin Cook

      Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth

        AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher

        by Zacks Equity Research

        AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.

          Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

          by Zacks Equity Research

          Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

            Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y

            by Zacks Equity Research

            Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.

              Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat

              by Zacks Equity Research

              Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents

                BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up

                by Zacks Equity Research

                BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.

                  Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates

                  by Zacks Equity Research

                  Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.

                    VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y

                    by Zacks Equity Research

                    VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents

                      Arpita Dutt headshot

                      6 FDA Events to Watch Out for in May 2017

                      by Arpita Dutt

                      Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

                        Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?

                        by Zacks Equity Research

                        Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.

                          Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up

                          by Zacks Equity Research

                          Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.

                            Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

                            by Zacks Equity Research

                            Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

                              by Arpita Dutt

                              Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

                                Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline

                                by Zacks Equity Research

                                Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .

                                  Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down

                                  by Zacks Equity Research

                                  Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL

                                    by Arpita Dutt

                                    Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.

                                      Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?

                                      by Zacks Equity Research

                                      Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.

                                        Is J&J's Pharma Sales Slowdown a Warning for Other Players?

                                        by Zacks Equity Research

                                        Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.

                                          Ryan McQueeney headshot

                                          After Johnson & Johnson Earnings, Buy These Pharma Stocks

                                          by Ryan McQueeney

                                          Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.

                                            Arpita Dutt headshot

                                            Did Pharma & Biotech M&As Pick Pace in Q1?

                                            by Arpita Dutt

                                            Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.

                                              5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now

                                              by Zacks Equity Research

                                              Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.

                                                Geron Stock Rises after Positive Interim Update on Imetelstat

                                                by Zacks Equity Research

                                                Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.

                                                  Arpita Dutt headshot

                                                  Forget Novartis, Buy These Two Pharma Stocks Instead

                                                  by Arpita Dutt

                                                  With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank.